Go to main page https://www.ascelia.com/



Oncoral in short

Oncoral is novel patented irinotecan chemotherapy tablet. With daily dosing, Oncoral has the potential to offer both efficacy and safety benefits to cancer patients compared to intravenous high-dose infusions at the hospital

Development plan – Phase 2 and onwards

The development plan is to conduct a Phase 2 study in gastric cancer and from there potential label expansion into other solid cancer indications.


Presentations (films)

Magnus Corfitzen - CEO
Oncoral strategic plans

Strategic plans for Oncoral and its potential role in as a novel chemotherapy tablet helping patients suffering from cancer

Carl Bjartmar – CMO
Oncoral development plan

Presentation of the unmet medical need to be filled by Oncoral as well as the clinical development plan

Prof. Jeff Evans - expert oncologist
Unmet medical need within gastric cancer

Oncology expert Prof. Jeff Evans talks about the great unmet need to develop novel drugs for the treatment of gastric cancer. Jeff Evans forms part of Ascelia Pharma's Scientific Advisory Board for Oncoral.

Here you will find all the relevant documents for the day

Oncoral - CEO presentation

Download presentation from the CEO.

Oncoral - CMO presentation

Download presentation from Chief Medical Officer.

Oncology expert - Prof. Jeff Evans

Download presentation from Oncology Expert, Prof. Jeff Evans

Press release